Retatrutide: The Triple Agonist Delivering 30% Weight Loss
Retatrutide hits three hormone receptors instead of one or two, and the results are unlike anything in the GLP-1 class - up to 30.3% body weight lost, a level previously reached only by bariatric surgery. Here is the full data, what the mechanism means for your body, and why buying it from a peptide site is a genuinely dangerous idea.
Last updated: August 3, 2026
Important: Retatrutide Is Not FDA Approved
Retatrutide is an investigational drug. It is not FDA approved, not available by prescription, and cannot be legally obtained for weight loss in the United States. No licensed pharmacy - including compounding pharmacies - can legally dispense it.
Websites selling "retatrutide" as a research peptide are not operating within any pharmaceutical quality framework. See our gray-market safety section below before considering any such source. If you want effective treatment today, FDA-approved and physician-supervised options are covered throughout this article.
Quick Answer
Retatrutide is Eli Lilly's triple hormone receptor agonist, targeting GLP-1, GIP, and glucagon receptors simultaneously. In the Phase 3 TRIUMPH-1 trial, participants lost an average of 28.3% of body weight (about 70.3 lbs) at 80 weeks, rising to 30.3% at 104 weeks. Notably, 45.3% of participants achieved 30% or more weight loss - a threshold historically associated with bariatric surgery rather than medication.
That makes it the most effective obesity drug ever tested. But it is not available, and it will not be for some time. In the meantime, tirzepatide (roughly 20-22%) and high-dose semaglutide (roughly 20.7%) are the strongest options you can actually get prescribed - and for most people, getting started now beats waiting for a drug with no approval date.
What Is Retatrutide?
Retatrutide is an investigational once-weekly injectable developed by Eli Lilly. Its distinguishing feature is that it activates three different hormone receptors at once: GLP-1, GIP, and glucagon. It is often called a "triple agonist" or "triple-hormone-receptor agonist."
To place it in context, here is how the obesity drug class has evolved:
| Generation | Example | Receptors Targeted | Typical Weight Loss |
|---|---|---|---|
| Single agonist | Semaglutide (Wegovy) | GLP-1 | ~15% |
| High-dose single | Wegovy HD 7.2 mg | GLP-1 | ~20.7% |
| Dual agonist | Tirzepatide (Zepbound) | GLP-1 + GIP | ~20-22% |
| Dual (glucagon) | Survodutide | GLP-1 + glucagon | ~19% |
| Triple agonist | Retatrutide | GLP-1 + GIP + glucagon | ~28-30% |
The pattern is clear: each additional receptor target has produced a meaningful jump in effectiveness. Retatrutide sits at the top of that progression. For the other emerging options, see our guides to survodutide and CagriSema.
Why Three Receptors Beat Two
Each receptor retatrutide targets does something different. Understanding the division of labor explains why the results are so much larger.
1. GLP-1 Receptor - Appetite Suppression
The familiar mechanism. GLP-1 activation reduces hunger signaling in the hypothalamus and brainstem, slows gastric emptying so you feel full longer, and quiets the intrusive food thoughts most patients call "food noise." This is what makes you eat less.
2. GIP Receptor - Enhanced Effect and Better Tolerance
GIP activation amplifies the metabolic benefits of GLP-1 while appearing to improve gastrointestinal tolerance. This is the addition that made tirzepatide outperform semaglutide, and it also plays a role in how the body handles fat storage and insulin sensitivity.
3. Glucagon Receptor - Increased Energy Expenditure
This is the differentiator. Glucagon receptor activation increases energy expenditure and promotes fat breakdown in the liver. Where GLP-1 and GIP primarily reduce how much you take in, glucagon increases how much you burn. Attacking both sides of the energy balance equation is why the numbers jump so sharply.
Why adding glucagon was counterintuitive: Glucagon raises blood sugar - it is the hormone that opposes insulin. Deliberately activating glucagon receptors in a metabolic drug sounds backwards. It works because the powerful glucose-lowering effect of simultaneous GLP-1 and GIP activation offsets glucagon's glucose-raising effect, leaving the increased energy expenditure as the net benefit. It is a genuinely elegant piece of pharmacology, and it only works because all three are combined.
Glucagon's effect on hepatic fat is also drawing significant research interest for fatty liver disease, which may end up being a second major indication for this drug class.
TRIUMPH-1 Results: 30% Weight Loss
TRIUMPH-1 is the Phase 3 obesity trial for retatrutide, and its results are the reason this drug dominates conversation in obesity medicine.
| Outcome | Result |
|---|---|
| Mean weight loss at 80 weeks | 28.3% (average 70.3 lbs) |
| Mean weight loss at 104 weeks | 30.3% |
| Participants losing 30% or more | 45.3% |
Two things stand out beyond the headline number.
First, weight loss kept going. Going from 28.3% at 80 weeks to 30.3% at 104 weeks means participants were still losing at the two-year mark. Most obesity medications plateau around 12 to 18 months as the body adapts. Continued loss into year two suggests the glucagon component may be partially counteracting the metabolic adaptation that normally stalls progress.
Second, nearly half crossed 30%. That 45.3% figure matters more than the average. A 30% total body weight reduction has historically been the domain of bariatric surgery. Getting close to half of participants there with a weekly injection is a categorical shift, not an incremental one.
To put 30% in perspective: a person starting at 250 lbs would end around 175 lbs. Someone starting at 300 lbs would end around 210 lbs.
The Phase 2 Data That Started the Hype
Before TRIUMPH-1, the Phase 2 trial published in the New England Journal of Medicine was what put retatrutide on everyone's radar. It tested weekly doses up to 12 mg.
At the 12 mg dose:
- More than 9 out of 10 participants lost at least 10% of their baseline body weight
- Nearly two thirds lost 20% or more
- Nearly half reached the highest weight loss thresholds measured
Broader analyses have reported roughly 92% of participants losing at least 5% and 75% losing at least 10%. Pooled analyses of weekly subcutaneous retatrutide have shown mean body weight reductions on the order of 10.66 kg across varied trial durations - a reminder that shorter studies and lower doses produce much smaller numbers than the 80- and 104-week Phase 3 headlines.
Read trial durations carefully. Retatrutide figures range from about 10 kg to over 30% of body weight depending on dose and how long the study ran. The 28-30% numbers come specifically from the highest doses over 80 to 104 weeks. Shorter exposure at lower doses produces far more modest results - which is also why anecdotal reports of rapid loss from unregulated sources tell you nothing reliable.
Retatrutide vs Tirzepatide vs Semaglutide
| Factor | Retatrutide | Tirzepatide (Zepbound) | Semaglutide (Wegovy) |
|---|---|---|---|
| Receptors | GLP-1 + GIP + glucagon | GLP-1 + GIP | GLP-1 |
| Weight loss | 28-30% | 20-22% | 15% (20.7% at HD) |
| FDA status | Investigational - not approved | Approved | Approved |
| Can you get it today? | No | Yes | Yes |
| Compounded version available? | No - illegal | Yes, through licensed programs | Yes, through licensed programs |
| Long-term safety data | Limited - trials ongoing | Established | Extensive, including CV outcomes |
The honest summary: retatrutide is meaningfully more effective on paper and completely unavailable in practice. Tirzepatide remains the most effective medication you can actually be prescribed. See our comparison of the best GLP-1 for weight loss for the options that exist today.
Is It Really Comparable to Bariatric Surgery?
The "matches bariatric surgery" framing is accurate on one specific measure and misleading on several others.
Where it holds up: Sleeve gastrectomy typically produces around 25-30% total body weight loss, and gastric bypass around 30-35%. Retatrutide's 30.3% at 104 weeks genuinely lands in that range, and the 45.3% of participants exceeding 30% is a surgical-tier outcome.
Where the comparison breaks down:
- Durability. Surgery permanently alters anatomy. Retatrutide works only while you take it. Every GLP-1 studied to date shows substantial regain after discontinuation, and there is no reason to expect retatrutide differs. See weight regain after stopping GLP-1 medications.
- Duration of evidence. Bariatric surgery has decades of follow-up data on mortality, diabetes remission, and long-term complications. Retatrutide has trial data measured in months.
- Cost over time. Surgery is a large one-time expense. An indefinite weekly injection is a recurring one that likely exceeds surgery's total cost within a few years.
- Reversibility. This cuts both ways - stopping a drug is easy, undoing surgery is not.
The realistic framing is that retatrutide may offer surgery-comparable weight loss as long as you keep taking it. That is a genuinely important development, but it is a different proposition from a one-time procedure.
Side Effects and Open Questions
Retatrutide's side effect profile in trials has been consistent with the GLP-1 class, and dose-dependent - higher doses produce more frequent and more intense effects.
Reported Effects
- Nausea - the most commonly reported effect, concentrated during dose escalation
- Vomiting - more frequent at higher doses
- Diarrhea - common across the class
- Constipation - often the most persistent complaint
- Reduced appetite - the intended effect, but it can become excessive
Questions That Are Not Yet Settled
These are the reasons approval requires time rather than enthusiasm, and they apply doubly to anyone contemplating an unregulated source:
- Muscle mass at 30% loss. Losing 70+ lbs means losing a large amount of tissue, and lean mass is always part of that. Whether the glucagon component helps or hurts body composition at this magnitude is an active research question. Our muscle loss prevention guide is essential reading for anyone on any high-efficacy agent.
- Effects of chronic glucagon receptor activation. Long-term consequences of sustained glucagon signaling are not fully characterized. It affects glucose production, liver metabolism, and cardiovascular parameters.
- Nutritional adequacy. Appetite suppression severe enough to drive 30% loss makes meeting protein, vitamin, and mineral needs genuinely difficult without structured guidance.
- Gallbladder risk. Gallstone risk tracks with the rate and magnitude of weight loss. At this magnitude, the risk warrants monitoring. See do GLP-1 agonists cause gallstones.
- Cardiovascular outcomes. Semaglutide has dedicated cardiovascular outcome trials behind it. Retatrutide does not yet.
None of these are reasons to think retatrutide will fail. They are reasons the drug is still in trials rather than on pharmacy shelves.
The Gray Market Problem: Read This
Because retatrutide's trial results are extraordinary and it is not available by prescription, a substantial online market has emerged selling vials labeled "retatrutide" as research chemicals or research peptides, typically with a "not for human consumption" disclaimer.
That disclaimer is not a formality. It is the legal mechanism that lets these vendors operate entirely outside pharmaceutical regulation.
What You Are Actually Risking
- Unknown identity. Nothing verifies the vial contains retatrutide. It could be a different peptide, a partially degraded one, or nothing active at all.
- Unknown potency. Even if the compound is correct, the actual concentration may bear no relationship to the label. With a drug this potent, a dosing error is not a minor issue.
- Unknown purity. Peptide synthesis produces byproducts. Pharmaceutical manufacturing removes them under validated processes with documented specifications. Research-grade production is not held to that standard.
- Sterility. These are injectable products. Non-sterile injectables cause abscesses, cellulitis, and bloodstream infections.
- No dosing guidance. There is no approved dosing schedule. People are self-selecting doses from internet forums for a drug that produces 30% body weight loss at studied doses.
- No medical supervision. No one is monitoring your labs, watching for pancreatitis, checking your gallbladder, or catching a dangerous interaction with your other medications.
- No recourse. If something goes wrong, there is no manufacturer, no pharmacy, and no regulatory body to turn to.
Compounded semaglutide and tirzepatide are a different thing entirely. Do not conflate the two. Licensed compounding pharmacies operating under sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act are state and federally regulated, are subject to inspection, and dispense only against a valid prescription from a licensed prescriber. That is a regulated healthcare channel. A research-peptide website is not, and no legitimate compounding pharmacy will produce retatrutide, because compounding an unapproved drug is not permitted.
If your goal is significant, medically supervised weight loss, the path is a licensed prescriber and an approved medication. Our guide to the best compounding pharmacy for semaglutide explains how to verify that a provider is operating legitimately.
What to Do While You Wait
There is a strong argument against waiting for retatrutide, even if you find the data compelling.
Approval timelines for obesity drugs are measured in years, not months, and they slip. Meanwhile, the health costs of carrying excess weight - on your joints, your cardiovascular system, your glucose metabolism, and your sleep - accrue continuously. Losing 20% of your body weight starting now is worth considerably more than losing 30% starting at some unspecified future date.
There is also a practical benefit to starting on an approved GLP-1: you learn how your body responds to this class of drug. You find out whether you tolerate them well, what your side effect pattern looks like, and how to structure your nutrition and training around appetite suppression. If retatrutide is eventually approved, you will transition into it as an experienced patient rather than a beginner.
- Tirzepatide is the most effective approved option at roughly 20-22%. See best tirzepatide online.
- Wegovy HD reaches about 20.7% for those who prefer semaglutide. See our Wegovy HD guide.
- Compounded semaglutide or tirzepatide through a licensed telehealth program is the affordable route for people without coverage.
- Build the foundation now. Protein intake, resistance training, and sleep determine how much of your loss is fat versus muscle - on any medication.
Start With an Approved Option Today
Retatrutide is not available, but physician-supervised compounded semaglutide is - starting at $249/month with the medical consultation, medication, shipping, and ongoing dose management included. No insurance required, and every step is handled by licensed clinicians.
Frequently Asked Questions
When will retatrutide be available?
No approval date has been set. Retatrutide remains investigational, with Phase 3 trials in the TRIUMPH program ongoing. Eli Lilly must complete those trials, submit a full application, and clear FDA review before it can be prescribed. Obesity drug timelines from Phase 3 completion to market are typically measured in years, and they frequently slip. Anyone promising you access now is not selling you a prescription drug.
How much weight can you lose on retatrutide?
In the Phase 3 TRIUMPH-1 trial, participants lost an average of 28.3% of body weight (about 70.3 lbs) at 80 weeks and 30.3% at 104 weeks. Roughly 45.3% of participants lost 30% or more. Earlier Phase 2 data at the 12 mg dose showed more than 9 in 10 participants losing at least 10%, and nearly two thirds losing 20% or more. These figures come from the highest doses over long durations - shorter or lower-dose exposure produces substantially less.
Can I buy retatrutide online?
Not legally, and not safely. Retatrutide is not FDA approved, so no pharmacy - including compounding pharmacies - can legally dispense it. Websites selling it as a "research peptide" operate entirely outside pharmaceutical regulation, which means no verified identity, potency, purity, or sterility, and no medical oversight. This is fundamentally different from compounded semaglutide from a licensed 503A or 503B pharmacy, which is a regulated healthcare channel.
How is retatrutide different from Mounjaro or Zepbound?
Tirzepatide (Mounjaro and Zepbound) is a dual agonist activating GLP-1 and GIP receptors. Retatrutide adds a third target, the glucagon receptor, which increases energy expenditure and promotes fat breakdown in the liver rather than only reducing intake. That third mechanism is the main reason retatrutide reaches 28-30% versus tirzepatide's 20-22%.
Does retatrutide burn fat or just suppress appetite?
Both, and that is what distinguishes it. The GLP-1 and GIP components reduce appetite and food intake. The glucagon component increases energy expenditure and promotes breakdown of fat stored in the liver. Working on both sides of the energy balance equation is the leading explanation for why it outperforms drugs that only reduce intake.
What are retatrutide's side effects?
Trial side effects have been consistent with the GLP-1 class and dose-dependent: nausea, vomiting, diarrhea, constipation, and reduced appetite, with the heaviest burden during dose escalation. Open questions that trials are still working through include the effect on lean muscle mass at 30% weight loss, the long-term consequences of chronic glucagon receptor activation, nutritional adequacy under severe appetite suppression, and cardiovascular outcomes.
Is retatrutide as good as bariatric surgery?
On the single measure of total body weight lost, 30.3% is genuinely comparable to sleeve gastrectomy (typically 25-30%). But surgery permanently alters anatomy while retatrutide works only while you take it, and the GLP-1 class consistently shows substantial regain after stopping. Surgery also has decades of long-term outcome data that retatrutide does not. Comparable weight loss is not the same as a comparable long-term intervention.
Should I wait for retatrutide instead of starting semaglutide or tirzepatide?
Generally, no. There is no approval date, obesity drug timelines run years and often slip, and the health costs of excess weight accumulate the entire time you wait. Starting an approved medication now also teaches you how your body responds to this drug class, which makes any future transition smoother. Losing 20% starting today is worth more than losing 30% starting at an unknown future date.
Why am I still hungry on a GLP-1 medication?
Several reasons are common: you may not be at a therapeutic dose yet, since appetite suppression builds through titration; hunger may be habitual or emotional rather than physiological; inadequate protein intake leaves genuine hunger signals intact; and poor sleep raises ghrelin and lowers leptin regardless of medication. Individual response also varies - some people are simply less sensitive to a given agent, which is a legitimate reason to discuss switching with your prescriber.
Will I regain the weight if I stop retatrutide?
Almost certainly, based on everything known about this drug class. GLP-1 medications manage appetite regulation rather than permanently resetting it, and studies consistently show substantial regain after discontinuation. Losing 30% and then stopping would likely produce proportionally large regain. Preserving muscle mass, sustaining high protein intake, and continuing resistance training meaningfully reduce how much returns.
Medical Disclaimer
This article is for informational purposes only and does not constitute medical advice. Retatrutide is an investigational drug that has not been approved by the FDA and is not available by prescription in the United States. Nothing in this article should be interpreted as encouragement to obtain retatrutide from any source. Clinical trial figures represent group averages from controlled studies and do not predict individual results. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or weight loss strategy. HealthyPound may receive compensation from affiliate partners mentioned in this article. See our affiliate disclosure and full medical disclaimer for more information.